**Supplemental section**

 **Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia**

**Supplemental methods**

**Inclusion and exclusion**

Patients were eligible for inclusion if they were receiving invasive mechanical ventilation, the treating clinician suspected pneumonia due to clinical and radiographic features and was planning to perform diagnostic bronchoscopy. Exclusions were lack of proxy decision maker to provide study assent and lack of study team available to perform the TaqMan array card assay (the study team were routinely unavailable from Friday 5pm to Monday 8am, and also sporadically unavailable due to leave). Proxy assent (nominated or personal consultee advice) was obtained prior to study inclusion, and retrospective consent was sought if capacity was regained whilst the patient remained in hospital. Patients were identified by the treating team and included prospectively and consecutively when the study team were available.

**Selection and validation of sequences for TaqMan array**

The local microbial ecology was reviewed using previous conventional microbiological culture data from the hospital. This was supplemented by review of the literature concerning causative organisms reported in ventilator-acquired and community-acquired pneumoniaE1 and the authors’ previous experience of molecular diagnostics in pneumonia.E2E,3 Species or genus-specific primer/probe sequences were identified by reviewing the literature for well cited and fully validated real-time PCR assays with the presumption that where possible each organism should be covered by two sequences to minimise false positive results. In the absence of a published validated assay, one was designed in-house normally targeting a housekeeping gene in the first instance (i.e. gyrB, rpoB, ssrA, dnaJ, recN) following the guidelines set out previously.E4 All assays were subjected to a comprehensive *in silico* analysis for possible cross-reactions with other high priority organisms and if necessary modified accordingly to remove any cross reaction. The species covered by the card are shown in main manuscript figure 1. The card was initially validated against our large bank of DNA extracts from a diverse range of microorganisms, known positive/negative clinical specimens, and all available EQA panels from Quality Control for Molecular Diagnostics ([www.qcmd.org](http://www.qcmd.org/)). A panel of 9 synthetic control plasmids containing all our target sequences (with 20 nucleotides each side of the primer target sites also included) were generated ([www.genscript.com](http://www.genscript.com/)) and used to quality check each batch of TAC plates and determine the limit of detection of each assay. As a demonstration of clinical utility complete concordance was achieved against the 5 organisms from the Quality Control for Molecular Diagnostics 2018 Sepsis EQA Pilot Study (*Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Enterococcus faecalis* -in transport media and blood, and *Candida albicans*- blood only) (table E1).

**Bronchoscopy procedure**

The bronchoscope was passed via the endotracheal tube and wedged in a sub-segmental bronchus of a segment corresponding to the area most affected on chest x-ray or CT chest. Where diffuse bilateral shadowing was present, either segment of the right middle lobe was used. A 20ml bronchiolar wash was administered with the return discarded before a 200 mL lavage was undertaken with the return pooled and transported to the laboratory for processing along with a 2.5 mL Ethylenediaminetetraacetic acid (EDTA) blood sample taken at the time of bronchoscopy. Where samples were taken out of hours (M-Thurs 5pm-8am and Sunday 8am-Monday 8am) samples were stored at 4oC prior to processing in hours, in accordance with existing laboratory procedures.

**Nucleic acid extraction**

Nucleic acid extraction from clinical samples was undertaken using the NUCLISENS easyMAG platform (Biomerieux,Marcy L’Etoile, France), in accordance with manufacturers’ instructions. Nucleic acids were extracted from 500 µL of input sample, with a dilution of MS2 bacteriophage added pre-extraction to act as an internal extraction and inhibition control.

**TaqMan Low-Density Array**

TaqMan Array Cards (ThermoFisher, Waltham, MA) are microfluidic cards with 8 specimen loading ports that lead to 48 inter-connected wells, each of which can be preloaded with the primers and probes necessary for independent simplex PCR reactions. Following completion of specimen loading, wells are sealed to create a closed system for each reaction to occur in parallel. Our 52-pathogen TAC used a collection of in-house primers, with more than one pan-specific or type-specific primer set included to increase overall specificity for a number of pathogens (main manuscript figure 1). The card also included primers to target the endogenous control RNase P, the internal control MS2, and the known genetic marker of *Staphylococcus aureus* virulence, Panton–Valentine leukocidin (PVL). Sequences on the card are available on request.

Cards were run on the QuantStudio 7 Flex platform (Thermo Fisher), following a modified version of the method previously described.E5 Briefly, 50 µL of each nucleic acid extract was mixed with 50 µL of TaqMan Fast Virus 1-step mastermix (Thermo Fisher) and 100 µL of RNase free water, before 98 µL was added in 2 consecutive sample loading ports covering all 96 targets. Reverse transcriptase real-time PCR was undertaken according to the following amplification protocol: 50˚C for 5 minutes, 95˚C for 20 seconds, then 45 cycles of 95˚C for 1 second followed by 60˚C for 20 seconds. Detection of a clear exponential amplification curve with a cycle threshold (CT) value ≤38 for any single gene target was reported as a positive result for the relevant pathogen.

**Conventional microbiology**

Samples were inoculated onto a range of solid agar and incubated in both air and 5-10% CO2 targeting conventional respiratory tract pathogens, *Staphylococcus aureus*, Enterobacteriales and Pseudomonads. Any organism with growth >104 cfu/mL was identified to species level using matrix assisted laser desorption isonisation time of flight (MALDI TOF) mass spectrometry (Bruker Ltd, Coventry, UK). A scanty mixed growth with no predominant organism was reported as ‘mixed respiratory tract flora’ and not characterised any further. Antimicrobial susceptibility was performed using disc diffusion as described by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).E6 Extended culture was performed for Legionella, Nocardia, Anaerobes, Fungi and Mycobacterium species.

A single in-house multiplex PCR assay formed the basis of conventional testing for common respiratory viruses (adenovirus, enterovirus, human metapneumovirus, influenza A virus, influenza B virus, parainfluenza virus, rhinovirus, and respiratory syncytial virus). In-house monoplex PCR assays were used for the detection of *Pneumocystis jirovecii* (PCP). *Aspergillus* spp. were tested for by culture on Sabouraud Dextrose Agar with Chloramphenicol, with or without testing for the presence of galactomannan antigen in serum (serum GM) and BAL (BAL GM) by Platelia™ *Aspergillus* enzyme immunoassay (Bio-Rad Laboratories, Hercules, CA). Infection with *Chlamydia* spp., *Coxiella burnetii,* or *Mycoplasma pneumoniae* was tested for by serology at the national reference laboratory (‘atypical serology’). As well as routine culture, *Legionella pneumophilia* serotype 1 were tested for by the detection of antigen in urine, using the Alere BinaxNOW™ Legionella Urinary Antigen Card (Thermo Fisher) with positive tests confirmed in the national reference laboratory.. Conventional laboratory methods were not routinely available to detect coronaviruses.

**Metagenomic sequencing**

Residual BAL samples (average 40 mL) from 98 out of the 100 patients were used for metagenomic sequencing. Two patients with suspected containment level 3 infections were excluded. BAL was centrifuged at 500 x g for 5 minutes to separate the host cells (pellet) from the bacterial, viral and fungal pathogens (supernatant). One mL of each sample supernatant was filtered through a 0.45 µm filter and used for viral RNA and DNA extraction using a QIAamp MinElute Virus Spin kit (Qiagen), using an on-column DNase step for viral RNA. Reverse transcription and random amplification of both viral DNA and cDNA was carried out as described previously.E7 The remaining supernatant was centrifuged at 3220 x g for 30 minutes and the pellet was subjected to host cell depletion using MolYsis Basic5 (Molzym, Bremen, DE) followed by bacterial/fungal DNA extraction using a QIAamp DNA Mini kit (Qiagen, Hilden, DE). Half of the DNA was submitted for HiSeq 4000 shotgun metagenomic sequencing, while the other half was used to amplify the 16S V4 region using barcoded primersE8,E9 and amplicons were sequenced by Illumina MiSeq sequencing. All samples were sequenced at the Wellcome Sanger Institute, and raw read data is available at the European Nucleotide Archive (ENA) with study accession numbers ERP111277, ERP111280, ERP112277, and ERP018622. Amplicon data was analysed using Qiime2 v2019.10.0E10. Single-end sequences were denoised using DeblurE11 and classified using a feature classifier built from the Greengenes 13\_8 99% OTUs taxonomy database. For metagenomic shotgun sequence data, human reads were first removed from the data using Bowtie2 v2.3.5.E12 Human-depleted paired reads were then classified using Kraken2 v2.0.8E13 .For bacterial targets, a curated bacterial database based on the Genome Taxonomy DatabaseE14 was used for classification. For viral and fungal pathogens, the standard Kraken2 viral and fungal databases were used. Qiime2 and Kraken2 tabular outputs were subsequently processed in RE15 to calculate the proportions of reads mapping to individual taxa for each sample.

The output for each of the sequencing approaches were compared to paired negative controls and analysed for the presence of fungal, viral and bacterial reads. Fungal and viral organisms were considered significant if they were the dominant species and/or the read counts was above the determined background levels. Bacterial organisms were considered significant if they were the dominant species with >45% reads or if they were identified by both shotgun and 16S amplicon sequencing with >20% reads. Organisms that fell below these thresholds but were found by TAC were included as low confidence hits (indicated in table E3).

**Supplemental results**

**Technical validation of the TAC**

To ensure cards were spotted correctly with the primers and probes in their assigned pods, nine synthetic plasmids constructs containing all the target sequences were processed to quality-check each new batch of TAC cards in a checker-board fashion (see supplemental section). All five microorganisms from the Quality Control for Molecular Diagnostics 2018 Sepsis EQA Pilot Study were successfully detected (table E1).

**Implementation of TaqMan array**

Our experience as researchers and clinicians leads us to tentatively suggest the following approach to using the card. Where a pathogenic organism(s) is detected at Ct value of </=32 antimicrobials can be adjusted to target the organism(s) detected, in light of known local resistance patterns and the patient's history of AMR carriage. Pathogenic organisms detected at a Ct of >32 are likely to be colonisers or contaminants, although detection of respiratory viruses or atypical organisms such as *Legionella sp* or *Mycoplasma pneumoniae* at higher Ct values remain significant. The use of organism abundance to distinguish colonisation from infection is an established practice in ventilated patientsE1, E16, with a cut-off of 104 colony forming units (CFU) commonly used E1,E16 . The detection of low pathogenicity organisms needs to be interpreted in light of the patient’s known or suspected immune status, amongst the immunocompromised high levels of such organisms, especially if the sole pathogen detected should prompt treatment. In patients in whom no relevant pathogens are detected (i.e. all organisms are at low levels, low pathogenicity organisms detected in immunocompetent hosts or no organisms are detected at all) consideration should be given to alternative sites of infection, alternative diagnoses and where clinical suspicion of infection is low, stopping antibiotics (figure E4).

**Supplemental references**

E1. Morris AC. Management of pneumonia in intensive care. *J Emerg Crit Care Med*. 2018;2:101.

E2. Jones N, Conway Morris A, Curran MD et al. Evaluating the use of a 22-pathogen TaqMan array card for rapid diagnosis of respiratory pathogens in Intensive Care. J Med Micro, in press.

E3. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. *Clin Infect Dis*. 2016;62(7):817-823.

E4. Heaney J, Rolfe K, Gleadall NS, Greatorex JS, Curran MD. Low-Density TaqMan® Array Cards for the Detection of Pathogens. In: *Current and Emerging Technologies for the Diagnosis of Microbial Infections*. Vol 42. Methods in Microbiology. Elsevier; 2015:199-218.

E5. Steensels D, Reynders M, Descheemaeker P, et al. Clinical evaluation of a multi-parameter customized respiratory TaqMan® array card compared to conventional methods in immunocompromised patients. *J Clin Virol*. 2015;72:36-41.

E6. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0, 2020 (available from [**http://www.eucast.org/clinical\_breakpoints/**.-accessed](http://www.eucast.org/clinical_breakpoints/.-accessed) 25/5/20)

E7. Lewandowska DW, Zagordi O, Geissberger F-D, et al. Optimization and validation of sample preparation for metagenomic sequencing of viruses in clinical samples. *Microbiome*. 2017;5(1):94.

E8. Caporaso JG, Lauber CL, Walters WA, et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc Natl Acad Sci USA*. 2011;108 Suppl 1:4516-4522.

E9. The Earth Microbiome Project (available from www.earthmicrobiome.org accessed 25/5/20)

E10. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol*. 2019;37(8):852‐857.

E11. Amir A, McDonald D, Navas-Molina JA, et al. Deblur Rapidly Resolves Single-Nucleotide Community Sequence Patterns. Gilbert JA, ed. *mSystems*. 2017;2(2):759–7.

E12. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. *Nat Methods*. 2012;9(4):357-359.

E13. Wood DE, Lu J, Ben Langmead. Improved metagenomic analysis with Kraken 2. *Genome Biol*. 2019;20(1):257.

E14. Parks DH, Chuvochina M, Waite DW, et al. A standardized bacterial taxonomy based on genome phylogeny substantially revises the tree of life. *Nature Biotechnology*. 2018;36(10):996-1004.

E15. R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.(available from <http://www.R-project.org/>)

E16. Plachouras D, Lepape A, Suetens C. ECDC definitions and methods for the surveillance of healthcare-associated infections in intensive care units. *Intensive Care Med*. October 2018:1-3

**Supplemental tables**

|  |  |  |
| --- | --- | --- |
| **Sample Content** | **Matrix\*** | **TaqMan array cards results (Ct Value)** |
| *Streptococcus pneumoniae* | TM | S pneumoniae #1 29.602 S pneumoniae #2 28.624Streptococcus spp #1 29.060 Streptococcus spp #2 29.027  |
| *Pseudomonas aeruginosa* | TM | P aeruginosa #1 28.806 P aeruginosa #1 28.350 |
| *Klebsiella pneumoniae* | TM | K pneumoniae #1 25.650 K pneumoniae #2 25.106 Enterobacteriaceae 26.922 |
| *Enterococcus spp* | TM | E faecalis ddl 26.641  |
| *Streptococcus pneumoniae* | Blood | S pneumoniae #1 31.353 S pneumoniae #2 30.811Streptococcus spp #1 31.735 Streptococcus spp #2 31.952  |
| *Candida albicans* | Blood | Candida albicans 34.313 Candida spp 33.124 Fungal 18S 30.839 |
| *Pseudomonas aeruginosa* | Blood | P aeruginosa #1 28.065 P aeruginosa #1 30.647 |
| *Klebsiella pneumoniae* | Blood | K pneumoniae #1 26.770 K pneumoniae #2 25.213 Enterobacteriaceae 26.715 |
| *Enterococcus spp* | Blood | E faecalis ddl 30.431  |
| Negative | Blood | PCR Negative |

**Table E1: Performance of TaqMan array card in the Public Health England Quality Control for Molecular Diagnostics 2018 Sepsis EQA Pilot Study (TM-transport medium)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Patient number** | **Results from Sample 1** | **Results from sample 2** | **Time gap between samples (days)** | **Change in management following initial result** |
| 33 | E faecium #1 24.697 E. faecium #2 Ct 24.763 , E. coli #1 Ct 25.932 E. coli #2 Ct 24.858 Enterobacteriaceae #1 Ct 25.693, Enterobacteriaceae Proteus #2 Ct 31.475 E. cloacae #2 32.970, Candida albicans Ct 32.379 Candida spp Ct 28.091 Fungal 18S Ct 28.742, HSV #1 Ct 34.709 Streptococcus ssp #1 Ct 34.036, CoN Staph Ct 34.774 Staph epidermidis Ct 35.190 | E faecium #1 Ct 36.332 E  faecalis ddi Ct 34.684 , E. coli #1 Ct 31.558 E. coli #2 Ct 30.792 Enterobacteriaceae #1 Ct 32.150 Enterobacteriaceae Proteus #2 Ct 34.699 E. cloacae #1 Ct 31.576 E. cloacae #2 Ct 36.190, Candida albicans Ct 36.004 Candida spp Ct 32.689 Fungal 18S Ct 34.139, Streptococcus ssp #1 Ct 29.937 | 11 | none |
| 55 | negative | negative | 13 | none |
| 58 | Streptococcus spp #1 Ct 32.597 Streptococcus spp #2 Ct 32.993, S. maltophilia Ct 34.504 CMV#2 Ct 38.142 | negative | 42 (two separate admissions to ICU within same episode of hospitalisation) | Planned PCP therapy withheld |
| 73 |  S. pneumoniae #1 Ct 22.937  S. pneumoniae #2 Ct 20.722 Streptococcus spp #1 Ct 21.796 Streptococcus spp #2 Ct 21.282  |  S. pneumoniae #1 Ct 27.069  S. pneumoniae #2 Ct 25.926  , Streptococcus spp #1 Ct 28.388 Streptococcus spp #2 Ct 27.479    | 4  | Clarithromycin stopped, tazocin de-escalated to co-amoxiclav |
| 80 | HPIV 3 #1 Ct 23.183  HPIV 3 #2 Ct 20.441  , Streptococcus spp #1 Ct 28.126 Streptococcus spp #1 Ct 27.987     | HPIV 3 #1 Ct 32.754  HPIV 3 #2 Ct 32.723      Streptococcus spp #1 Ct 37.390  | 7  | none |
| 93 |  P. aeruginosa #1 Ct 27.570  P. aeruginosa #2 Ct 25.586 , CMV #2 Ct 31.394, S. aureus (nuc)#1 Ct 34.856 S. aureus (nuc)#2 Ct 35.580 | P. aeruginosa #1 Ct 25.602  P. aeruginosa #2 Ct 25.167 , CMV #2 Ct 30.602, S. aureus (nuc)#1 Ct 32.462 S. aureus (nuc)#2 Ct 32.247, Streptococcus spp #1 Ct 35.626 Streptococcus spp #2 Ct 33.058, S. pyogenes #1 Ct 34.013 S. pyogenes #2 Ct 34.016, E. coli #1 Ct 30.0 E. coli #1 Ct 31.904 Enterobacteriaceae #1 33.452 | Obtained at the same time from right upper lobe (anterior segment) and right lower lobe (superior segment) | none |

**Table E2: results from TaqMan array of lavage from 6 patients with two samples.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Sample** | **TaqMan\_hits** | **Ct values** | **Conventional****Microbiology** | **Microbial****Sequencing** | **Total Validated** |
| 1 | Coronavirus OC43 | 28.914/25.624 |  | ✓ | ✓ |
| 2 | Legionella pneumophila | 30.75/33.226 | ✓ | ✓ | ✓ |
| 3 | Flu B | 35.259/25.714 | ✓ |  | ✓ |
| *Staphylococcus aureus nuc (unreported)* | *36.177/34.185* |  | Staph. aureus |  |
| 4 | Flu A | 25.969 | ✓ | ✓ | ✓ |
| Flu A H3\* | 25.714 | ✓ |  | ✓ |
| Staphylococcus aureus | 26.829/27.302 | ✓ | ✓ | ✓ |
| 5 | Escherichia coli | 34.711/36.142 |  |  |  |
| Enterobacteriaceae\* | 35.102 |  |  |  |
| 6 | negative | - | ✓ | ✓ | ✓ |
| 7 | CoN Staph\* | 33.536 |  | ✓ | ✓ |
| Staphylococcus epidermidis | 34.469 |  | ✓ | ✓ |
| *MecA\*\** | *30.995* |  |  |  |
| 8 | negative | - | ✓ | ✓ | ✓ |
| 9 | Coronavirus NL63 | 38.115 |  |  |  |
| 10 | Rhinovirus | 28.447/32.301 | ✓ | ✓ | ✓ |
| Flu B | 30.274/29.312 | ✓ | ✓ | ✓ |
| Klebsiella pneumoniae | 28.097/28.871 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 28.025 |  | ✓ | ✓ |
| Enterococcus faecium | 33.835/33.564 |  | (✓) | ✓ |
| 11 | Streptococcus pneumoniae | 29.48/27.47 |  | ✓ | ✓ |
| 12 | CMV | 29.516 | ✓ | ✓ | ✓ |
| Pneumocystis jirovecii | 33.628 | ✓ | ✓ | ✓ |
| EBV | 35.57 |  |  |  |
| Rhinovirus | 38.933 |  |  |  |
| 13 | Candida albicans | 31.653 | ✓ | ✓ | ✓ |
| Candida sp\* | 29.997 |  | ✓ | ✓ |
| 14 | Pneumocystis jirovecii | 28.901 | ✓ | ✓ | ✓ |
| 15 | Flu B | 27.081/26.365 | ✓ | ✓ | ✓ |
| CMV | 35.85 |  |  |  |
| *Enterococcus faecium (unreported)* | *33.746* | ✓ | ✓ |  |
| *Enterococcus faecium ddl (unreported)* | *33.697* | ✓ |  |  |
| 16 | CoN Staph\* | 30.462 |  | ✓ | ✓ |
| Staphylococcus epidermidis | 28.874 |  |  |  |
| *MecA\*\** | *30.331* |  |  |  |
| Strep pneumoniae | 31.451 |  |  |  |
| Streptococcus sp\* | 28.021/28.858 |  |  |  |
| 17 | Negative | - | ✓ | ✓ | ✓ |
| 18 | Flu A | 36.073/36.538 | ✓ |  | ✓ |
| Flu A H3\* | 34.436 | ✓ |  | ✓ |
| Stenotrophomonas maltophilia | 25.179 | ✓ | ✓ | ✓ |
| Streptococcus pneumoniae | 35.94 |  |  |  |
| 19 | HSV | 31.549/29.524 | ✓ | ✓ | ✓ |
| CoN Staph\* | 31.255 |  |  |  |
| Staphylococcus epidermidis | 29.453 |  |  |  |
| 20 | Escherichia coli | 23.612/21.367 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 22.459 |  | ✓ | ✓ |
| Stenotrophomonas maltophilia | 18.458 | ✓ | ✓ | ✓ |
| 21 | Streptococcus pneumoniae | 27.833/25.957 |  | ✓ | ✓ |
| Streptococcus sp\* | 27.02/27 |  | ✓ | ✓ |
| 22 | CoN Staph\* | 31 |  | ✓ | ✓ |
| Staphylococcus epidermidis | 30.38 |  |  |  |
| *MecA\*\** | *25.421* |  |  |  |
| CMV | 34.007 | ✓ | ✓ | ✓ |
| 23 | Rhinovirus | 29.647/28.918 | ✓ | ✓ | ✓ |
| 24 | Rhinovirus | 22.857/22.678 | ✓ | ✓ | ✓ |
| Serratia marcescens | 30.211/32.342 | ✓ |  | ✓ |
| Streptococcus sp | 31.931/31.859 |  |  |  |
| Moraxella catarrhalis | 33.513 |  |  |  |
| Haemophilus influenzae | 37.097/35.339 |  |  |  |
| 25 | negative | - | ✓ | ✓ | ✓ |
| 26 | Enterobacter cloacae | 27.988/27.995 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 24.71 | Citrobacter freundii | ✓ | ✓ |
| Serratia marcescens | 28.617 |  |  |  |
| Staph epidermidis | 34.237 |  |  |  |
| Streptococcus sp | 31.147/30.041 |  |  |  |
| 27 | Enterobacter cloacae | 27.985/29.587 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 29.57 |  | ✓ | ✓ |
| Staph aureus | 31.504/32.666 |  | (✓) | ✓ |
| Klebsiella pneumoniae | 32.867/35.422 |  |  |  |
| Escherichia coli | 33.854/33.858 |  |  |  |
| Streptococcus sp | 34.628/35.956 |  |  |  |
| Enterococcus faecalis ddl | 33.792 |  |  |  |
| 28 | Enterobacter cloacae | 33.815/negative |  | ✓ | ✓ |
| Enterobacteriaceae\* | 32.809 |  | ✓ | ✓ |
| Escherichia coli | 35.635/33.746 |  | Citrobacter freundii |  |
| Enterococcus faecium ddl\* | *34.716* |  |  |  |
| Enterococcus faecium | 33.823 |  | (✓) | ✓ |
| 29 | negative | - | ✓ | ✓ | ✓ |
| 30 | HSV | 24.247 | ✓ | ✓ | ✓ |
| *HSV (gly D)\** | *21.052* |  |  |  |
| 31 | Pneumocystis jirovecii | 34.719 | ✓ |  | ✓ |
| 32 | HSV | 27.422 | ✓ | ✓ | ✓ |
| *HSV (gly D)\** | *26.085* |  |  |  |
| Streptococcus sp | 33.859/34.864 |  |  |  |
| Escherichia coli | 34.092/24.28 |  |  |  |
| Enterobacteriaceae\* | 33.079 |  |  |  |
| 33 | Enterococcus faecium | 24.697/24.763 |  | ✓ | ✓ |
| Escherichia coli | 25.932/24.858 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 25.693 |  | ✓ | ✓ |
| Enterobacteriaceae proteus | 31.475 |  |  |  |
| Enterobacter cloacae | 32.97 |  |  |  |
| Candida albicans | 32.379 |  | ✓ | ✓ |
| Candida sp\* | 28.091 |  | ✓ | ✓ |
| HSV | 34.709 | ✓ | ✓ | ✓ |
| Streptococcus sp | 34.036 |  |  |  |
| CoN Staph\* | 34.774 |  |  |  |
| Staphylococcus epidermidis | 35.19 |  |  |  |
| 34 | Candida albicans | 33.758 |  | ✓ | ✓ |
| Candida sp\* | 30.328 |  | ✓ | ✓ |
| 35 | Legionella sp | 26 |  |  |  |
| Enterobacter cloacae | 32/34.407 |  |  |  |
| 36 | Enterococcus faecium | 36.332 |  |  |  |
| Enterococcus faecalis ddl | 34.684 |  |  |  |
| Escherichia coli | 31.558/30.792 |  |  |  |
| Enterobacteriaceae\* | 32.15 |  | (✓) | ✓ |
| Enterobacteriaceae proteus | 34.699 |  |  |  |
| Enterobacter cloacae | 31.576/36.19 |  |  |  |
| Candida albicans | 36.004 |  | ✓ | ✓ |
| Candida sp\* | 32.689 |  | ✓ | ✓ |
| Streptococcus sp | 29.937 |  | ✓ | ✓ |
| 37 | Parainfluenza virus 3 | 35.369/41.282 | ✓ | ✓ | ✓ |
| Staphylococcus aureus (nuc) | 30.789/30.654 |  | ✓ | ✓ |
| 38 | HSV | 31.677 | ✓ | ✓ | ✓ |
| *HSV (gly D)\** | *29.263* |  |  |  |
| 39 | Escherichia coli | 27.94/26.445 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 23.316 |  | ✓ | ✓ |
| CoN Staph | 32.182 |  |  |  |
| 40 | EBV | 24.242 | ✓ | ✓ | ✓ |
| 41 | Pseudomonas aeruginosa | 23.611/22.519 |  | ✓ | ✓ |
| Enterococcus faecium | 29.525 | ✓ | ✓ | ✓ |
| *Enterococcus faecium ddl (unreported)* | *29.579* |  |  |  |
| CMV | 35.431 |  |  |  |
| Aspergillus | 35.341/34.13 | raised BAL galactomannan |  |  |
| 42 | negative | - |  |  |  |
| *E. faecium ddl (unreported)* | *36.189* | E. faecium | E. faecium |  |
| 43 | HSV (glyD) | 33.006 |  |  |  |
| 44 | Streptococcus sp | 30.006 |  |  |  |
| HSV | 35.306 |  |  |  |
| 45 | negative | - | ✓ | ✓ | ✓ |
| 46 | negative | - | ✓ | ✓ | ✓ |
| 47 | Rhinovirus | 26.152/26.565 | ✓ | ✓ | ✓ |
| Streptococcus spp | 32.849/32.483 |  |  |  |
| 48 | HSV | 27.708 | ✓ | ✓ | ✓ |
| *HSV (gly D)\** | *27.032* |  |  |  |
| *49* | *Candida albicans* | *30.832* |  | *ND* |  |
| *Candida sp\** | *27.08* |  | *ND* |  |
| *Staphylococcus aureus* | *34.675/34.785* |  | *ND* |  |
| *EBV* | *32.954* |  | *ND* |  |
| *Streptococcus sp* | *34.315/33.935* |  | *ND* |  |
| 50 | Klebsiella pneumoniae | 23.332/23.759 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 25.06 |  | ✓ | ✓ |
| Candida albicans | 32.985 |  |  |  |
| Candida sp\* | 31.006 |  |  |  |
| Streptococcus sp | 30.845/30.889 |  |  |  |
| Staphylococcus epidermidis | 35.43 |  |  |  |
| Stenotrophomonas maltophilia | 35.615 |  |  |  |
| Escherichia coli | 34.143/33 |  |  |  |
| 51 | Rhinovirus | 24/23.572 | ✓ | ✓ | ✓ |
| Pseudomonas aeruginosa | 27.782/27.393 |  | ✓ | ✓ |
| Serratia marcescens | 31/ 30.756 |  |  |  |
| Enterobacteriaceae | 29.107 |  |  |  |
| 52 | Streptococcus pneumoniae | 26.865/26.814 |  | ✓ | ✓ |
| Haemophilus influenzae | 29.252/32.253 |  | ✓ | ✓ |
| Streptococcus sp\* | 27.818/28 |  | ✓ | ✓ |
| 53 | negative | - | ✓ |  |  |
| *Legionella sp (unreported)* | *late Ct* |  | Legionella sp |  |
| 54 | EBV | 32.612 |  |  |  |
| Escherichia coli | 33.168/32.146 |  |  |  |
| Enterobacteriaceae\* | 33.3 |  | ✓ | ✓ |
| Streptococcus sp | 35.839 |  |  |  |
| 55 | negative | - | ✓ | ✓ | ✓ |
| 56 | negative | - | ✓ | ✓ | ✓ |
| 57 | HSV | 36.732 |  |  |  |
| *HSV (glyD)\** | *33.212* |  |  |  |
| Candida albicans | 30.441 |  | ✓ | ✓ |
| Candida sp\* | 30.721 |  | ✓ | ✓ |
| Streptococcus sp | 32.424/31.792 |  | ✓ | ✓ |
| 58 | Streptococcus sp | 32.597/32.993 |  | (✓) | ✓ |
| Stenotrophomonas maltophilia | 34.504 |  |  |  |
| CMV | 38.142 | ✓ | ✓ | ✓ |
| 59 | negative | - | ✓ | ✓ | ✓ |
| 60 | negative | - | ✓ | ✓ | ✓ |
| 61 | Flu A | 23.472/23.884 | ✓ | ✓ | ✓ |
| Flu A H12009\* | 24.68 | ✓ |  | ✓ |
| Human coronavirus | 33.525 |  |  |  |
| 62 | negative | - | ✓ | ✓ | ✓ |
| 63 | Escherichia coli | 26.8/25.518 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 26.842 |  | ✓ | ✓ |
| Streptococcus sp | 31.943/31.95 |  |  |  |
| 64 | Flu A | 31.786/33.092 | ✓ | ✓ | ✓ |
| Flu A H12009\* | 34.195 | ✓ |  | ✓ |
| Staphylococcus aureus | 32.593/33.529 | ✓ | ✓ | ✓ |
| Streptococcus sp | 30.185/31.04 |  | (✓) | ✓ |
| EBV | 35 |  |  |  |
| 65 | Haemophilus influenzae | 29.796/31.514 |  | ✓ | ✓ |
| Staphylococcus aureus | 30.433/30.241 |  | ✓ | ✓ |
| Streptococcus pneumoniae | 33.693/34.986 |  |  |  |
| Streptococcus sp\* | 33.271/34.49 |  |  |  |
| 66 | Flu A | 24.032/24.258 | ✓ | ✓ | ✓ |
| Flu A H12009\* | 25.498 | ✓ |  | ✓ |
| Staphylococcus aureus | 31.403/31.307 |  | ✓ | ✓ |
| 67 | Flu A | 24.553/25.573 | ✓ | ✓ | ✓ |
| Flu A H12009\* | 27.372 | ✓ |  | ✓ |
| 68 | Escherichia coli | 28.879/26.58 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 27.3 |  | ✓ | ✓ |
| 69 | Pseudomonas aeruginosa | 22.442/21.451 | ✓ | ✓ | ✓ |
| 70 | negative | - | ✓ | ✓ | ✓ |
| *71* | *Flu A* | *19.057/18.981* | *✓* | *ND* | ✓ |
| *Flu A H12009\** | *19.359* |  | *ND* |  |
| *Staphylococcus epidermidis* | *30.847* |  | *ND* |  |
| *CoN Staph\** | *28.31* |  | *ND* |  |
| *Mec A\*\** | *30.342* |  | *ND* |  |
| 72 | Klebsiella pneumoniae | 30.116/30.92 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 31.642 |  | ✓ | ✓ |
| *Enterococcus faecium ddl\** | *34.138* |  |  |  |
| Enterococcus faecium | 29.631 |  |  |  |
| Streptococcus sp | 31.071/30.46 |  | ✓ | ✓ |
| Candida albicans | 30.627 |  | ✓ | ✓ |
| Candida sp\* | 28.094 |  | ✓ | ✓ |
| 73 | Streptococcus pneumoniae | 22.937/20.722 | ✓ | ✓ | ✓ |
| Streptococcus sp\* | 21.796/21.282 |  | ✓ | ✓ |
| 74 | Candida albicans | 31.319 |  | ✓ | ✓ |
| Candida sp\* | 28.695 |  | ✓ | ✓ |
| 75 | Candida albicans | 30.957 |  | ✓ | ✓ |
| Candida sp\* | 28.145 |  | ✓ | ✓ |
| Streptococcus sp | 32.386/33.246 |  | (✓) | ✓ |
| 76 | Streptococcus pneumoniae | 27.069/25.926 |  | ✓ | ✓ |
| Streptococcus sp\* | 28.388/27.479 |  | ✓ | ✓ |
| 77 | Klebsiella pneumoniae | 30.352/29.557 |  |  |  |
| Enterobacteriaceae\* | 31.192 |  | ✓ | ✓ |
| Enterococcus faecalis ddl | 32.972 |  |  |  |
| 78 | *Enterococcus faecium ddl\** | *28.78* |  |  |  |
| Enterococcus faecium | 27.461 | mixed upper respiratory tract flora | ✓ | ✓ |
| Candida sp | 29.432 |  | ✓ | ✓ |
| Staph epidermidis | 32.993 |  |  |  |
| CoN Staph\* | 35.849 |  |  |  |
| *Mec A\** | *33.906* |  |  |  |
| 79 | negative | - | ✓ | ✓ | ✓ |
| 80 | Parainfluenza virus 3 | 23.183/20.441 | ✓ | ✓ | ✓ |
| Streptococcus sp | 28.126/27.987 |  | ✓ | ✓ |
| 81 | Enterobacter cloacae | 33.627/33.121 |  |  |  |
| Enterobacteriaceae\* | 32.732 |  |  |  |
| 82 | Parainfluenza virus 3 | 32.754/32.723 | ✓ | ✓ | ✓ |
| Streptococcus sp | 37.39 |  | ✓ | ✓ |
| 83 | Human metapneumovirus | 20.726 | ✓ | ✓ | ✓ |
| *Staphylococcus epidermidis (unreported)* | *36.35* |  | Staph. epidermidis |  |
| 84 | Parainfluenza virus 3 | 29.652/29.798 | ✓ | ✓ | ✓ |
| 85 | Enterobacter cloacae | 33.48/36.535 |  |  |  |
| Enterobacteriaceae\* | 34.897 | Rhinovirus |  |  |
| Streptococcus sp | 33.522 |  |  |  |
| 86 | negative | - | ✓ | ✓ | ✓ |
| 87 | Streptococcus pneumoniae | 25.414/24.813 |  | ✓ | ✓ |
| Streptococcus sp\* | 27.097/26.671 |  | ✓ | ✓ |
| 88 | Pneumocystis jirovecii | 27.175 | ✓ | ✓ | ✓ |
| 89 | negative | - | ✓ | ✓ | ✓ |
| 90 | negative | - | ✓ | ✓ | ✓ |
| 91 | Escherichia coli | 26.282/25.058 | ✓ | ✓ | ✓ |
| Enterobacteriaceae\* | 25.284 |  | ✓ | ✓ |
| Streptococcus sp | 29.341/29.195 |  | ✓ | ✓ |
| EBV | 33.843 |  |  |  |
| 92 | Candida albicans | 34.63 |  | ✓ | ✓ |
| Candida sp\* | 31.566 |  | ✓ | ✓ |
| Streptococcus sp | 35.922/38.979 | Rhinovirus |  |  |
| 93 | Pseudomonas aeruginosa | 27.57/25.586 | ✓ | ✓ | ✓ |
| CMV | 31.394 | detected later | ✓ | ✓ |
| Staphylococcus aureus (nuc) | 34.856/35.58 |  | ✓ | ✓ |
| Streptococcus sp\* | 35.626/33.058 |  |  |  |
| Streptococcus pyogenes | 34.013/34.016 |  |  |  |
| Escherichia coli | 30/31.904 |  |  |  |
| Enterobacteriaceae\* | 33.452 |  |  |  |
| 94 | Mycoplasma pneumoniae | 30.119/25.063 |  | ✓ | ✓ |
| 95 | negative | - | ✓ | Staphylococcus sp |  |
| 96 | Rhinovirus | 33.484/32.082 | ✓ | ✓ | ✓ |
| HSV | 31.272 | ✓ | ✓ | ✓ |
| *HSV (glyD)\** | *29.312* |  |  |  |
| 97 | Rhinovirus | 32.087/26.5 | ✓ | ✓ | ✓ |
| Streptococcus sp | 32.477/35.637 |  | ✓ | ✓ |
| CMV | 39.35 | detected later |  |  |
| 98 | Candida albicans | 28.705 |  | ✓ | ✓ |
| Candida sp\* | 25.94 |  | ✓ | ✓ |
| Pseudomonas aeruginosa | 32.878/33.959 |  |  |  |
| 99 | Legionella spp | 16.766 |  | ✓ | ✓ |
| HSV | 37.136 |  |  |  |
| 100 | negative | - | ✓ | ✓ | ✓ |

**Table E3: TaqMan results showing all individual target hits with Ct values and whether validated by conventional microbiology and/or microbial sequencing. \*Not included in validation numbers as duplicate at sub-species or genus level detection, \*\*MecA was not included in validation numbers. Samples from patients 049 and 071 were not sequenced (ND). (**✓**) indicates low confidence hits (only detected by 16S, read counts <45%, Genus level only).**

|  |  |  |
| --- | --- | --- |
| **Organism** | **Conventional testing** | **TaqMan array card** |
| **Bacteria** |  |  |
| *Citrobacter koseri\*\** | 1 | 0 (not on card) |
| *Enterococcus faecium* | 1 | 0 |
| Coagulase negative *Staphylococci\*\** | 1 | 0 |
| *Streptococcus pneumoniae* | 0\* | 5 |
| **Fungi** |  |  |
| *Pneumocystis jirovecii* | 0 | 1 |
| **Viruses** |  |  |
| Adenovirus | 0 | 1 |
| Cytomegalovirus | 1 | 6 |
| Epstein Barr Virus | 1 | 8 |
| Herpes Simplex virus | 1 | 2 |
| Rhinovirus | 0 | 1 |

**Table E4: comparison of conventional microbiology for bloodstream infection with TaqMan microarray. \*none of the blood cultures taken at the time of bronchoscopy were positive for *S. pneumoniae*, however one patient with BAL culture positive streptococcal pneumonia had a positive blood culture for this organism taken 12 hours previously. \*\*positive in one of two bottles only.**

|  |  |  |
| --- | --- | --- |
| **De-escalation decisions** | Stopping macrolides  | 14 |
| Stopping carbapenem or anti-pseudomonal penicillin | 10 |
| Narrowing from carbapenem/antipseudomonal penicillin to narrower spectrum penicillin | 7 |
| Stopping septrin  | 6\* |
| Stopping antivirals  | 3 |
| Stopping aminoglycosides | 2 |
| Stopping other agents | 6 |
| **Escalation decisions** | Start antivirals | 7 |
| Start antifungals | 3 |
| Broadened gram negative cover (add aminoglycoside or carbapenem) | 3 |
| Add glycopeptide | 4 |
| Add cover for atypical organism | 1 |

\*two reduced to prophylactic dose

Table E5: Detail of changes in antibiotic therapy resulting from TAC. Some patients had more than one change.

**Supplemental figures**

**(see attached PDF)**

**Figure E1: workflow for patients with suspected pneumonia admitted to Intensive Care.** Upper panel shows conventional workflow

Lower panel shows workflow following implementation of the TaqMan array card. Economic analysis was undertaken for the laboratory tests indicated in column 4



**Figure E2: Time to result for conventional culture and TAC. P value by Wilcoxon matched pairs signed rank test**

**Figure E3: frequency of co-detection of organisms, visual summary of data drawn from table E3.**



**Figure E4: Schematic representation of the proposed clinical decision tree arising from the results of the TaqMan array**.